BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mori JO, Shafran JS, Stojanova M, Katz MH, Gignac GA, Wisco JJ, Heaphy CM, Denis GV. Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins. Prostate 2022. [PMID: 35403746 DOI: 10.1002/pros.24351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Mandl A, Markowski MC, Carducci MA, Antonarakis ES. Role of bromodomain and extraterminal (BET) proteins in prostate cancer. Expert Opin Investig Drugs 2023;:1-16. [PMID: 36857796 DOI: 10.1080/13543784.2023.2186851] [Reference Citation Analysis]
2 Kemble J, Kwon ED, Karnes RJ. Addressing the need for more therapeutic options in neuroendocrine prostate cancer. Expert Rev Anticancer Ther 2023;23:177-85. [PMID: 36698089 DOI: 10.1080/14737140.2023.2173174] [Reference Citation Analysis]
3 Basak D, Gregori L, Johora F, Deb S. Preclinical and Clinical Research Models of Prostate Cancer: A Brief Overview. Life (Basel) 2022;12:1607. [PMID: 36295041 DOI: 10.3390/life12101607] [Reference Citation Analysis]
4 Liu Z, Zhang Y, Xiang Y, Kang X. Small-Molecule PROTACs for Cancer Immunotherapy. Molecules 2022;27:5439. [DOI: 10.3390/molecules27175439] [Reference Citation Analysis]